| ¿µ¹® | insulin | ÇÑ±Û | Àν¶¸° |
|---|---|---|---|
| ¼³¸í | ÀÌÀÚ ¶û°ÖÇѽº¼¶ÀÇ B¼¼Æ÷°¡ ÇÕ¼º-ºÐºñÇϴ ȣ¸£¸ó ´Ü¹éÁú, Æ÷µµ´çÀ» ±Û¸®ÄÚ°ÕÀ¸·Î ¹Ù²Ù´Â È£¸£¸ó´Ü¹éÁú·Î, ºÐÀÚ·®Àº 5,807ÀÌ´Ù. Ç÷ÁßÀÇ ´ç³óµµ »ó½ÂÀ¸·Î ÀÎÇÏ¿© ºÐºñ°¡ ÃËÁøµÈ´Ù. ±ÙÀ°-Áö¹æÁ¶Á÷-°£ µî Ç¥Àû¼¼Æ÷ÀÇ ¼ö¿ëü ´Ü¹éÁú°ú °áÇÕÇÏ¿© Á¤º¸¸¦ ¼¼Æ÷³»·Î Àü´ÞÇÔÀ¸·Î½á Ç÷¾× Áß¿¡¼ ´ç, ÁöÁú, ¾Æ¹Ì³ë»ê ´ë»ç¸¦ Á¶ÀýÇÑ´Ù. ´çÀÇ Á¶Á÷¿¡ ¹Þ¾Æµå¸®´Â °ÍÀ» ÃËÁøÇÏ¿© Ç÷´çÀ» ÀúÇϽÃŲ´Ù. »ý¼º-ºÐºñ·® ÀúÇÏ, Á¶Á÷¼¼Æ÷ÀÇ ¼ö¿ëü ºÎÁ·Àº °íÇ÷´çÀÇ ¿øÀÎÀÌ µÈ´Ù. ¶ÇÇÑ ¾Æ¹Ì³ë»êÀÇ Èí¼ö¿Í ´Ü¹éÁú, Áö¹æÀÇ ÇÕ¼ºÀ» ÃËÁøÇϸç Áö¹æºÐÇØ´Â ¾ïÁ¦ÇÑ´Ù. Àν¶¸°Àº ÀÌÀÚȰ¼º¼ººÐÀÇ ¾àǰÀ¸·Î¼ ´ç´¢º´ ¹× ±âŸ ÁúȯÀÇ Ä¡·á¿¡ »ç¿ëµÈ´Ù. Àν¶¸°À̶ó´Â ¸íĪÀº ¼¶À̶õ ¶æÀÇ ¶óƾ¾îÀÎ insula¿¡¼ ¿¬À¯ÇÑ´Ù. 1921³â ij³ª´ÙÀÇ ÀÇ»ç F.G. ¹êÆÃ°ú C.H. º£½ºÆ®¿¡ ÀÇÇÏ¿© óÀ½À¸·Î ÀÌÀÚ¿¡¼ äÃëµÇ¾ú°í, ±× ÈÄ Àν¶¸°ÀÇ °áÁ¤À» ¾ò°Ô µÇ¾ú´Ù. F. »ý°Å¿¡ ÀÇÇØ¼ ¼ÒÀÇ Àν¶¸°ÀÇ ±¸Á¶°¡ ¹àÇôÁ³´Âµ¥(1955), À̰ÍÀº ´Ü¹éÁú Áß¿¡¼´Â ÃÖÃÊ·Î ±¸Á¶½ÄÀÌ ¹àÇôÁø °ÍÀÌ´Ù. Æ÷µµ´çÀ¸·ÎºÎÅÍ ±Û¸®ÄÚ°ÕÀÇ »ý¼º, Æ÷µµ´çÀÇ »êÈ ¹× Áö¹æÀ¸·ÎÀÇ ÀüÈ µîÀ» ÃËÁøÇÏ´Â ÀÛ¿ëÀÌ ÀÖ´Ù. µû¶ó¼ Àν¶¸°ÀÇ ¼ö¿ë¾×À» ÁÖ»çÇϸé Ç÷´çÀÌ ÀúÇÏÇϹǷΠ´ç´¢º´ÀÇ Ä¡·á¿¡ ¾²ÀδÙ. ¶Ç Àν¶¸°À» ÇÇÇÏ¿¡ ´ë·® ÁÖ»çÇϸé È¥¼ö¿¡ ºüÁö´Â °ÍÀ» ÀÌ¿ëÇÏ¿© Á¤½Åº´ Ä¡·á¿¡ Àν¶¸°¼îÅ©¿ä¹ýÀ¸·Î¼ ¾²ÀδÙ. |
||
| ¿µ¹® | IDDM(Insulin-Dependent Diabetes Mellitus) | ÇÑ±Û | Àν¶¸°ÀÇÁ¸´ç´¢º´ |
|---|---|---|---|
| ¼³¸í | IDDMÀº ´ç´¢º´ÀÇ Ä¡·á¿¡ ¹Ýµå½Ã Àν¶¸°ÀÌ ÇÊ¿äÇÑ °æ¿ì¸¦ ¸»ÇÑ´Ù. ÁÖ·Î ¿øÀÎÀÌ ÀÌÀÚ¿¡ ÀÖ´Â Àν¶¸°À» ºÐºñÇÏ´Â ¼¼Æ÷ÀÇ ÆÄ±«À̸ç ÀÌ·Î ÀÎÇØ¼ ´ç´¢º´ÀÇ Ä¡·áÁ¦·Î ¾²ÀÌ´Â Àν¶¸°ÀÇ ºÐºñ¸¦ ÃËÁøÇÏ´Â ¾à¹°ÀÌ ÀÌ IDDM¿¡¼´Â ¾²ÀÏ ¼ö°¡ ¾ø°í ¿ÀÁ÷ Àν¶¸°¸¸ÀÌ Ä¡·áÁ¦·Î ¾µ ¼ö°¡ ÀÖ´Ù. ÀüÇüÀûÀÎ Àν¶¸° ÀÇÁ¸Çü ´ç´¢º´Àº ¼Ò¾Æ¿¡¼ ÈçÈ÷ ¹ß»ýÇϰí Àν¶¸° ºÐºñ¼¼Æ÷ÀÇ ÆÄ±«¿¡ ÀÇÇØ¼ Àν¶¸° ºÐºñ´ÉÀº °ÅÀÇ ¾ø´Ù. |
||
| NPH | 1) Neutral Protamine Hagedorn Insulin = Isophane Insulin Susp... |
|---|---|
| AITT | arginine insulin tolerance test; augmented insulin tolerance test |
| IRI | immunoreactive insulin; insulin resistance index |
| IRS | immunoreactive secretion; infrared spectrophotometry; insulin receptor species; insulin receptor sub... |
| IST | inappropriate sinus tachycardia; insulin sensitivity test; insulin shock therapy; International Soci... |
| Grb2 | Growth Factor Receptor-Bound protein 2 |
|---|---|
| LSA | Lipid Bound Sialic Acid |
| NTBI | Non-transferrin-bound iron |
| PBI | Protein-bound iodine |
| MB | membrane bound |
IGF-II : insulin like growth factor-IIÀÇ ¾àÀÚ. ¸¹Àº Àå±â¿Í Á¶Á÷¿¡ ÀÛ¿ëÇÏ¿© ´Ü¹é ÇÕ¼º°ú DNA, RNAÀÇ ÇÕ¼ºÀ» Áõ°¡½ÃÄÑ ¼¼Æ÷ÀÇ ¼ö¿Í ¾çÀ» Áõ°¡
| bound | The external or limiting line, either real or imaginary, of any object or space; that which limits or restrains, or within which something is limited or restrained; limit; confine; extent; boundary. "He hath compassed the waters with bounds." (Job xxvi. 10) "On earth's remotest bounds." (Campbell) "And mete the bounds of hate and love." (Tennyson) To keep within bounds, not to exceed or pass beyond assigned limits; to act with propriety or discretion. Synonym: See Boundary. Origin: OE. Bounde, bunne, OF. Bonne, bonde, bodne, F. Borne, fr. LL. Bodina, bodena, bonna; prob. Of Celtic origin; cf. Arm. Bonn boundary, limit, and boden, bod, a tuft or cluster of trees, by which a boundary or limit could be marked. Cf. Bourne. Source: Websters Dictionary (01 Mar 1998) |
|---|---|
| bound water | Water held to colloids and other substances and not removed by simple filtration. (05 Mar 2000) |
| cell-bound antibody | A term used for antibody on the surface of cells that may be bound either through antigen combining sites or other sites such as the Fc region. (05 Mar 2000) |
| membrane-bound proton-translocating PPi synthase | <enzyme> From rhodospirillum rubrum; functions as an alternative coupling factor; n,n'-dicyclohexylcarbodiimide-sensitive; catalyses the phosphorylation of pi to ppi, the hydrolysis of ppi and the concomitant translocation of proton across the plasma membrane Registry number: EC 3.6.1.- Synonym: h(+)-ppi synthase (26 Jun 1999) |
| wood-bound | Incumbered with tall, woody hedgerows. Source: Websters Dictionary (01 Mar 1998) |
| muscle-bound | Denoting a condition in which individual muscles are overdeveloped but dyssynergic in concerted action. (05 Mar 2000) |
| protein-bound iodine | Thyroid hormone in its circulating form, consisting of one or more of the iodothyronines bound to one or more of the serum proteins. (05 Mar 2000) |
| protein-bound iodine test | A formerly used test of thyroid function in which serum protein-bound iodine is measured to provide an estimate of hormone bound to protein in peripheral blood. Synonym: PBI test. (05 Mar 2000) |
| amorphous insulin zinc suspension | Sterile suspension of insulin in buffered water for injection, modified by the addition of zinc chloride such that the solid phase of the suspension is amorphous; it contains 40 or 80 units per ml; the duration of action is equivalent to that of insulin injection. Synonym: amorphous insulin zinc suspension, semilente insulin. (05 Mar 2000) |
| anti-insulin | A factor, usually an antibody, which antagonises the action of insulin. (05 Mar 2000) |
| anti-insulin antibody | A serologic blood test that is used to detect antibodies to insulin. This test is performed in insulin dependent diabetics who exhibit insulin resistance. The presence of antibodies denotes a positive result. (27 Sep 1997) |
| biphasic insulin | <protein> A type of insulin that is a mixture of intermediate- and fast-acting insulin. (09 Oct 1997) |
| receptors, insulin | Cell surface proteins that bind insulin and trigger intracellular changes which influence the behaviour of cells. The best understood physiological consequence of insulin receptor activation is increased transport of glucose into most cells, which controls the rate of carbohydrate metabolism. The insulin receptor is a multifunctional protein complex that has intrinsic tyrosine kinase activity and is capable of autophosphorylation. (12 Dec 1998) |
| receptors, insulin-like-growth factor I | Specific proteins on or in cells to which insulin-like growth factor I (somatomedin c) binds and thereby modifies the function of the cells. These receptors contain transmembrane and cytosolic domains, bind igf-I preferentially, and have high-affinity sites for igf-II. The alpha-subunit has a mw of 130 kD and the beta subunit possesses tyrosine kinase activity. (12 Dec 1998) |
| receptors, insulin-like-growth-factor II | Specific proteins on or in cells to which insulin-like growth factor II and mannose-6-phosphate bind and thereby modify the function of the cells. These receptors have a mw of 250 kD and possess no tyrosine kinase activity. (12 Dec 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|